DDInter781 DDInter1409
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS.
Fosinopril {u} (Compound) resembles {v} (Compound) Enalapril
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Fosinopril {u} (Compound) resembles {v} (Compound) Enalapril
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Fosinopril {u} (Compound) binds {v} (Gene) SLC15A1
SLC15A1 {u} (Gene) is bound by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Fosinopril {u} (Compound) resembles {v} (Compound) Lisinopril
Lisinopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Fosinopril {u} (Compound) resembles {v} (Compound) Enalapril
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Sodium sulfate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Fosinopril {u} (Compound) upregulates {v} (Gene) SYNGR3
SYNGR3 {u} (Gene) is upregulated by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Fosinopril {u} (Compound) causes {v} (Side Effect) Muscular weakness
Muscular weakness {u} (Side Effect) is caused by {v} (Compound) Fluvastatin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Fosinopril {u} (Compound) resembles {v} (Compound) Enalapril
Enalapril {u} (Compound) resembles {v} (Compound) Captopril
Captopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Fosinopril {u} (Compound) resembles {v} (Compound) Enalapril
Enalapril {u} (Compound) resembles {v} (Compound) Trandolapril
Trandolapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Peginterferon beta-1a
Fosinopril {u} (Compound) resembles {v} (Compound) Lisinopril
Lisinopril {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Peginterferon beta-1a
Fosinopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Fosinopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Fosinopril (Compound) binds SLC15A1 (Gene) and SLC15A1 (Gene) is bound by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Fosinopril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Fosinopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Fosinopril (Compound) upregulates SYNGR3 (Gene) and SYNGR3 (Gene) is upregulated by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Fosinopril (Compound) causes Muscular weakness (Side Effect) and Muscular weakness (Side Effect) is caused by Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Fosinopril (Compound) resembles Enalapril (Compound) and Enalapril (Compound) resembles Captopril (Compound) and Captopril may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Fosinopril (Compound) resembles Enalapril (Compound) and Enalapril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Fosinopril (Compound) resembles Lisinopril (Compound) and Lisinopril may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a